Probiotics are defi ned as live microorganisms that, when administered in adequate amounts, confer a health benefi t on the host, including the gastrointestinal tract. While this benefi cial effect was originally thought to stem from improvements in the intestinal microbial balance, there is now substantial evidence that probiotics can also provide benefi ts by modulating immune functions. In animal models, probiotic supplementation is able to provide protection from spontaneous and chemically induced colitis by downregulating infl ammatory cytokines or inducing regulatory mechanisms in a strain-specifi c manner. In animal models of allergen sensitization and murine models of asthma and allergic rhinitis, orally administered probiotics can straindependently decrease allergen-specifi c IgE production, in part by modulating systemic cytokine production. Certain probiotics have been shown to decrease airway hyperresponsiveness and infl ammation by inducing regulatory mechanisms. Promising results have been obtained with probiotics in the treatment of human infl ammatory diseases of the intestine and in the prevention and treatment of atopic eczema in neonates and infants. However, the fi ndings are too variable to allow fi rm conclusions as to the effectiveness of specifi c probiotics in these conditions.
Introduction
The gastrointestinal tract constitutes an important interface between host and environment and, as such, has the dual role of excluding pathogens while facilitating the absorption of nutrients. It is colonized by an estimated 10 14 microbes, with the density of colonization increasing from the stomach to the distal colon. Only a minority (300-500) of the species present in the intestinal microfl ora can currently be cultured in vitro, whereas a vast majority of intestinal microorganisms cannot. Commensal bacteria participate in both tasks of the gastrointestinal tract: some help in the absorption of otherwise indigestible nutrients, especially complex carbohydrates, and some contribute to colonization resistance, that is, the ability to inhibit colonization or overgrowth of potentially pathogenic microorganisms, by producing antimicrobial substances, competing for adhesion sites and nutrients, and stimulating the immune system.
Recent research efforts have demonstrated that infl ammation and immunity changes in general are critical to the development of nearly every complex condition, as well represented by the autoimmunity scenario, which now involves new, previously unsuspected clinical entities 1 and mechanisms. 2 Similarly, recent evidence has provided new insights into the immune-mediated mechanisms in metabolic diseases. 3, 4 Taken together, the cumulative data argue for the need to determine new tools to modulate immunity either by enhancing (as in the case of immunodefi ciencies) or by suppressing (such as in the case of allergy) the immune response, and dietary components are ideal candidates in this regard.
Probiotics are frequently, though not necessarily, commensal bacteria. The most widely accepted defi nition of probiotics states that they are live microorganisms that, when administered in adequate amounts, confer a health benefi t on the host. 5 In order to qualify as probiotic, microorganisms should fulfi ll most, if not all, of the criteria listed in Table 1 . The established probiotics that meet these criteria are generally lactic acid bacteria (LAB), most commonly Lactobacillus and Bifidobacterium species, but Lactococcus, Streptococcus, and Enterococcus species, as well as some nonpathogenic strains of Escherichia coli, and certain yeast strains also qualify. Numerous other LAB have shown probiotic potential in animal studies. In recent years, evidence has accumulated that probiotic strains can exhibit the same activities as commensal bacteria, including immunomodulation.
Gut-associated lymphoid tissue (GALT) is the largest lymphoid tissue of the human body. Its earliest and largest exposure to microbial antigens occurs during the initial intestinal colonization, which starts at birth. The type of colonizing organisms depends on the mode of birth and the mode of feeding, hygiene levels, and medication use. A fairly stable confi guration of permanently colonizing bacteria is reached in children by approximately 4 years of age. The stimuli provided by colonization with commensal bacteria are essential for the development of a fully functional and balanced immune system, including not only homing of B and T cells to the lamina propria and expansion and maturation of IgA plasmocytes and IgA production but also the induction of tolerance toward innocuous food and microbial antigens.
GALT can be divided into areas where lymphocytes are scattered throughout the epithelium and the lamina propria and organized lymphoid tissues, including Peyer's patches and mesenteric lymph nodes (MLNs). 6 Intestinal antigens are delivered to Peyer's patch dendritic cells (DCs) via specialized enterocytes called M cells. In addition, lamina propria DCs have been shown to directly sample antigens, including enteropathogenic and commensal bacteria, in the intestinal lumen via transepithelial dendrites without jeopardizing the integrity of the epithelial barrier. 7, 8 This process can be induced by ligation of any of a variety of Toll-like receptors (TLRs) expressed on epithelial cells. 9 Whereas priming of T cells in Peyer's patches or MLNs leads to effective local (mucosal) immune responses or tolerance depending on the encountered antigen, systemic immune responses or tolerance to ingested antigens are likely to be generated in the MLNs. 6 The translocation effi ciency of commensal (and presumably probiotic) bacteria depends on the bacterial strain and the luminal concentration, 10, 11 but the percentage of orally administered commensal bacteria that can be recovered from DCs in MLNs is very small. 12 Effi cient killing by macrophages and sequestering in MLN DCs largely prevent commensal bacteria from gaining access to the systemic immune compartment. 10, 12 This indicates that intestinal DC populations are central to the immune-modulating effects of commensal and, by extension, probiotic bacteria.
DCs are critical players in both innate and adaptive immunity since they are the most potent antigenpresenting cells and have the ability to activate naïve T cells. 13 In addition, they have a critical role in directing helper T-cell responses toward Th1 or Th2, or regulatory patterns. 13 Th1 immune responses critically depend on the ability of DCs to produce interleukin (IL)-12 and are characterized by the production of interferon (IFN)-γ and IL-2, which induce cell-mediated immunity. Th2 immune responses involve IL-4, IL-5, IL-6, and IL-13 and induce humoral immunity. There is now substantial evidence that DCs can direct T cells to assume regula- • At least one phase 2 study, preferably independent confi rmation of results by another center Stable during processing and storage tory functions and thereby induce oral tolerance. 6, 14 One of the most extensively studied mechanisms for the induction of regulatory T cells by DCs is the release of IL-10 or transforming growth factor (TGF)-β, resulting in Tr1 and Th3 cells regulatory T cells that act through the secretion of IL-10 and TGF-β, respectively. Other mechanisms involve the production of immunosuppressive IFN-α or the induction of indoleamine 2,3-dioxygenase (IDO), which is an immunoregulatory enzyme with key functions in the interactions between DCs and regulatory T cells that ultimately result in immunosuppression. DC immaturity or partial maturation at the time of antigen presentation has also been implicated in tolerance induction, 15 particularly as a result of their interaction with apoptotic cells. 16 Since tolerance to innocuous food and commensal antigens is a prerequisite for gastrointestinal immune homeostasis, it is not surprising that intestinal DCs differ phenotypically, and functionally, from peripheral DCs in that they preferentially prime antigen-specifi c CD4+ T cells to produce Th2 cytokines or to differentiate into regulatory T cells and induce tolerance. 6, 14 Yet, it remains unclear whether this tolerogenic phenotype of intestinal DCs is due to their derivation from distinct lineages, their tissue microenvironment, or, in the case of commensal and other nonpathogenic bacteria, to differential stimuli provided by key bacterial components. For further data on mucosal immunity and its relationship to disease, we refer to the recent literature. [17] [18] [19] [20] [21] [22] [23] [24] [25] In vitro effects of probiotics on DC phenotype and function
In their immature state, DCs are characterized by high capacity for antigen uptake. 13 Once they capture an antigen in the presence of appropriate infl ammatory stimuli, they migrate to secondary lymphoid organs and simultaneously undergo a maturation process. This process involves the upregulation of major histocompatibility complex (MHC) molecules for antigen presentation and of costimulatory molecules, such as CD40, CD54, CD83, and B7.1 and B7.2 (CD80 and CD86) for effective T-cell stimulation. Phenotypic maturation is accompanied by stimulus-specifi c enhancement of the production of various cytokines that shape the subsequent T, B, and natural killer (NK) cell responses. In recent years, numerous studies have examined how known and potential probiotics infl uence DC maturation and cytokine secretion. Because intestinal DCs are diffi cult to isolate in suffi cient numbers, these experiments have focused almost exclusively on human DCs derived from peripheral blood monocytes and on murine bone marrow-derived DCs (BMDCs). There are indications that DCs from the peripheral compartment respond differently to commensal bacteria than do MLN DCs. 26 However, there are also data suggesting that the responses of peripheral (human blood) and colonic lamina propria DCs to cell wall components of probiotic strains are qualitatively, though not quantitatively, similar. 27 However, blood myeloid DCs respond differently from monocyte-derived DCs (MDDCs) to probiotic bacteria of intestinal origin. 28 Therefore, it remains unclear to what extent the results obtained with MDDCs accurately refl ect the responses of at least a subset of intestinal DCs. Nonetheless, as is discussed in other sections of this review, certain characteristics of human MDDCs and murine BMDCs correspond rather well to the results of in vivo studies.
Incubation of live or UV-killed probiotics and other LAB induces distinct and strain-specifi c maturation and cytokine patterns in both human MDDCs and murine BMDCs (see Tables 2-4) . Overall, there are at least two types of LAB: strong and weak inducers of IL-12 and 202 used γ-irradiated bacteria tumor necrosis factor (TNF)-α production; however, almost all of them induce signifi cant, though quite variable, levels of IL-10. Most Bifi dobacterium strains stimulate the production of high levels of IL-10, but only modest levels of IL-12 and TNF-α, and this is also the pattern seen with Gram-negative bacteria of the intestinal microfl ora.
28-30
The results of coincubation experiments indicate that there are considerable interactions between bacterial strains that can result in the inhibition or enhancement of DC maturation and IL-12 and IL-10 induction, depending on the combination. 30, 31 Similar fi ndings have been reported in LAB-stimulated peripheral blood mononuclear cells (PBMCs). 32, 33 This suggests that the intestinal microfl ora of the host may have a decisive infl uence on the response to treatment with a specifi c probiotic. Note, however, that this inhibitory effect of weak IL-12 inducers on the inducing capacity of strong inducers is DC-subset dependent, with inhibition seen in MDDCs, but not in blood myeloid DCs. 28 Therefore, it remains to be established whether lamina propria DCs are sensitive to the inhibitory effect of the simultaneous presence of strong and weak IL-12 inducers.
DCs that undergo partial or full maturation after incubation with a particular LAB strain also differ in their capacity to stimulate allogeneic/autologous T-cell proliferation and cytokine production 27, [34] [35] [36] and to enhance NK cell cytokine production and cytotoxicity. 28, 31 In addition, when DC maturation is induced by lipopolysaccharide (LPS) with or without added TNF-α and IL-1β, the mere presence of certain LAB strains during this maturation process affects the ability of DCs to polarize the cytokine production of CD4+ T cells. 37 Using a similar protocol, it can be shown that Lactobacillus rhamnosus GG (LGG) is able to induce T-cell hyporesponsiveness 38 and that Lactobacillus reuteri 
Interactions between bacteria, intestinal epithelial cells, and DCs
There are complex and dynamic interactions between the intestinal epithelium and bacteria on the luminal side, and between the epithelium and the underlying immune system on the basolateral side. Intestinal epithelial cells are able to distinguish pathogenic from nonpathogenic bacteria on the basis of their invasiveness and the presence of fl agella, 41 although the exact mechanisms that allow them to do so are not fully elucidated and likely involve additional mucosal factors. 17 Intestinal epithelial cells that have encountered certain bacteria participate in the immune response by producing chemokines and cytokines and upregulating adhesion molecules, thereby attracting and activating immune cells.
This aspect has been largely neglected in investigations of the infl uence of probiotics on DC function. There are, however, studies showing that probiotics and other nonpathogenic LAB or components thereof strain-specifi cally affect the production of the chemokine IL-8 and of proinfl ammatory cytokines by intestinal epithelial cells. [42] [43] [44] [45] [46] [47] [48] This ability is further modulated by the presence of leukocytes on the basolateral part of the culture plates. 49 In turn, experiments where bacteria are added to the apical side and DCs to the basolateral side of an intestinal epithelial cell monolayer show that the presence of intestinal epithelium affects the ability of probiotic and other bacteria to induce DC maturation, and particularly the ratio of IL-10 to IL-12 that these DCs release. 41, 42 In addition, the small fraction of DCs that directly sample bacteria by extending dendrites across the intestinal epithelial layer are activated to a different extent than those that only come into contact with soluble mediators produced by epithelial cells that have encountered these bacteria. 41 Interestingly, DCs treated with supernatant fractions of epithelial cell-bacteria cocultures or of epithelial cells alone were found to preferentially drive Th2 or regulatory T-cell responses, that is, to induce a "mucosal" DC phenotype, even though peripheral MDDCs were used in these experiments. 41, 42 The production of TGF-β and thymic stromal lymphopoietin by intestinal epithelial cells has been implicated in the induction of this tolerogenic DC phenotype.
42,50

Probiotics in clinical practice
Probiotics in infl ammatory diseases of the bowel
Crohn's disease (CD) and ulcerative colitis (UC) are two distinct clinical forms of infl ammatory bowel disease (IBD), characterized by chronic relapsing intestinal infl ammation that is thought to result, similar to other autoimmune diseases, from complex interactions between genetic, [51] [52] [53] [54] environmental, [55] [56] [57] [58] [59] [60] and immunological factors. 19, [61] [62] [63] [64] Loss of tolerance to the patient's own commensal fl ora has been implicated in the development of both diseases. Decreased levels of Bifi dobacterium and Lactobacillus strains have been described in fecal samples, whereas raised counts of Enterococcus and Bacteroides species are found in infl amed mucosa of patients with IBD. High levels of infl ammatory cytokines (TNF-α and IL-1β) and IL-8 are produced by infl amed colonic mucosa of both UC and CD patients, [65] [66] [67] [68] [69] while the role of autoantibodies remains to be determined. 70 In addition, lamina propria T cells from IBD patients secrete elevated levels of IL-6, and IL-6/STAT-3 signaling is upregulated. 71, 72 However, there are differences between the two clinical forms of IBD, with lamina propria T cells from CD patients showing Th1 polarization, whereas those of UC patients express Th2 cytokines. 73 In addition, there is enhanced production of IL-10 in colonic tissue of UC patients. Interestingly, the vast majority of studies report that natural FoxP3+ CD4+CD25+ regulatory T cells (Tregs) are markedly expanded in colonic lamina propria and MLNs of both UC and CD patients, particularly during active disease, and are functionally normal in vitro. [74] [75] [76] [77] [78] While data in celiac disease are awaited, 25, 79 imbalanced microbiota and increased production of proinfl ammatory cytokines have also been implicated in irritable bowel syndrome (IBS) and in pouchitis. The latter is an infl ammatory condition of the ileal reservoir in patients with ileal pouch anal anastomosis, a surgical procedure used in the management of UC. We note recent literature that reviews the issues of infl ammation, redox, and autoimmunity. [80] [81] [82] [83] [84] [85] [86] [87] [88] The effectiveness of probiotics in clinical trials with UC and CD patients Because of the potential of certain probiotic strains to infl uence the intestinal microbial balance, improve mucosal barrier function, and modulate immune responses, there have been numerous randomized controlled clinical trials of probiotic supplementation in IBD patients. Their results indicate that certain probiotics, including E. coli Nissle 1917, LGG, and the probiotic mixture VSL#3 are as effective as standard therapy (most frequently mesalazine) in inducing or maintaining remission in UC or maintaining remission in CD. 73, [89] [90] [91] However, when added to standard therapy, these and other probiotics do not provide additional benefi ts compared with standard therapy alone, and most of the probiotics tested to date are not more effective than placebo in inducing or maintaining remission in CD or UC. Only the results of some small trials suggest that various combinations of Bifi dobacterium strains are superior to placebo in preventing relapse in UC.
Supplementation of UC patients with a combination of Bifi dobacterium breve strain Yakult, Bifi dobacterium bifi dum strain Yakult, and an unspecifi ed strain of Lactobacillus acidophilus was associated with signifi cantly lower clinical activity index, endoscopic activity index, and histological scores compared with mesalazine alone. 90 In a small study of patients with UC, symbiotic treatment with Bifi dobacterium longum plus fructooligosaccharides and inulin, in addition to their existing medical therapy, tended to lower the sigmoidoscopy score (P = 0.06 compared with placebo).
92 Supplementation with a variety of probiotic strains was also reported to be associated with benefi cial effects on IBS. 73 In addition, VSL#3 was reported to prevent the onset of pouchitis.
The mechanisms by which probiotics might ameliorate IBD, IBS, and pouchitis are rarely addressed in these clinical trials. The symbiotic treatment that tended to lower the sigmoidoscopy score was associated with signifi cantly reduced mRNA expression of TNF-α and IL-1α in biopsy specimens. 92 In an open-label study of VSL#3 in patients that had recovered from acute pouchitis after antibiotic treatment, supplementation with this probiotic mixture also decreased the pouch levels of proinfl ammatory cytokines (TNF-α, IL-1α and IFN-γ), while it increased the production of IL-10. 93 Similarly, in patients with IBS, supplementation with Bifi dobacterium infantis 35624 or L. rhamnosus GR-1 plus L. reuteri RC-14 decreased IL-12 production and normalized the IL-10:IL-12 ratio. 94, 95 In addition, administration of VSL#3 resulted in the expansion of colonic Foxp3+ Tregs in conjunction with signifi cantly reduced pouchitis disease activity scores, 96 and supplementation with L. rhamnosus GR-1 and L. reuteri RC-14 was associated with an increased frequency of peripheral Tregs in IBS patients. 95 In healthy volunteers, it was shown that consumption of LGG led to downregulation of the production of proinfl ammatory cytokines and enhanced the ex vivo synthesis of IL-4 and IL-10 of their CD4+ T cells in response to stimulation with intestinal bacterial preparations. 97 Since infl ammatory reactions to the host's own microfl ora are implicated in IBD, the ability of LGG to skew microfl ora-induced cytokine production toward an anti-infl ammatory profi le could be of great benefi t. Note, however, that intestinal CD4+ T cells from CD patients and healthy volunteers show differential IFN-γ and IL-10 responses to stimulation with autologous intestinal bacteria or with sonicates of probiotics. 98 Therefore, it needs to be established whether LGG supplementation can have the same anti-infl ammatory effects in IBD patients as those seen in these healthy volunteers.
Data from in vitro studies with infl amed ileal tissue from CD patients suggest that L. casei DN-114001 can not only downregulate TNF-α and IL-6 production but also increase the percentage of lymphocytes undergoing apoptosis, which may contribute to its ability to diminish the number of activated T cells in the lamina propria.
67-69 Downregulation of IL-6, which can exhibit antiapoptotic activity, may play a role in this process. 69 Indeed, in a mouse model of chronic colitis, treatment with neutralizing IL-6 receptor antibodies prevented macroscopic signs of infl ammation in the colon while markedly increasing the number of lamina propria CD4+ T cells undergoing apoptosis. 99 Probiotics in animal models of colitis There are numerous animal models of colitis. Mice deficient in IL-10 or IL-2 (IL-10 −/− and IL-2 −/− mice) and HLA-B27 transgenic rats spontaneously develop colitis if they are not kept in germ-free conditions, which highlights the importance of the intestinal microfl ora in these models. Other models of chronic colitis include the transfer of CD4 + CD45RB high or CD4 + CD62L + T cells into severe combined immunodefi ciency (SCID) mice. In addition, chronic colitis can be induced by the intrarectal administration of trinitrobenzene-sulfonic acid (TNBS). In all of these models, colitis is T-cell mediated and involves mononuclear infi ltration of the colonic mucosa along with enhanced production of proinfl ammatory cytokines. Administration of dextran sodium sulfate (DSS) in the drinking water induces a model of acute colitis that requires neither B nor T cells, but is largely macrophage mediated. Although a mononuclear infi ltrate is also seen in the colon of DSS-treated mice, the damage is thought to be due mostly to the toxic effects of DDS rather than the infl ammation. Most available studies focused on the role of various probiotic in the prevention of colitis. None of the strains examined to date was completely effective. However, downregulating the production of proinfl ammatory cytokines and other infl ammatory mediators seems to constitute important mechanisms for the partial amelioration of colitis seen with numerous LAB strains in various models. 48, [100] [101] [102] Of note, TNF-α blocking agents are also quite successful in the treatment of patients with CD.
In addition, the ability to dampen Th1 responses (IL-12 and IFN-γ production) has been implicated in the preventative effect of Lactobacillus salivarius subspe-cies (ssp.) salivarius 433118 and B. infantis 35624, 103 the therapeutic effect of DNA isolated from VSL#3, 48 and the partial protection provided by preventative and therapeutic administration of L. plantarum 299v in IL-10 −/− mice. 104 Interestingly, in SCID mice reconstituted with activated CD4+ T cells or CD4+CD62L+ T cells, preventative treatment with a combination of L. reuteri DSM 12246 and L. rhamnosus 19070-2 or with E. coli Nissle was associated with signifi cantly decreased production of Th2 cytokines by polyclonally stimulated MLNs. 105, 106 However, the release of IFN-γ was also lower in both studies, although this reached signifi cance only with E. coli Nissle. In both cases, IL-10 levels were not signifi cantly affected.
A recent study investigated whether the transfer of LAB-treated DCs could protect mice from the development of TNBS-induced colitis. 107 Lactobacillus salivarius Ls33 and L. rhamnosus Lr32 were found to be weak inducers of DC maturation and cytokine production. Administration of BMDCs that had been incubated with one of these two LAB strains partially protected mice from TNBS-induced colitis, and this protection was greater than that achieved with intraperitoneal (i.p.) administration of the same LAB strain. This amelioration of colitis was shown to depend on the presence of CD4+CD25+ regulatory T cells, but to be independent of IL-10. Instead, it was associated with highly increased expression of IDO and IFN-γ. Production of this cytokine by DCs is known to induce IDO expression. This suggests that the partial maturation of DCs in the presence of L. salivarius Ls33 and L. rhamnosus Lr32 resulted in the induction of a tolerogenic DC phenotype.
Whereas the preceding studies do not provide evidence for a signifi cant role of IL-10, other data suggest an important function for this anti-infl ammatory and regulatory cytokine in the protection from recurrence of colitis in HLA-B27 transgenic mice associated with consumption of LGG. 102 In addition, the ability of various LAB strains to induce a high ratio of IL-10/IL-12 production in human PBMCs correlated with their capacity to provide signifi cant protection from TNBSinduced colitis. [108] [109] [110] Increasing the production of IL-10 by lamina propria T cells was also found to be an important mechanism in the ability of VSL#3 to reduce the severity of recurrent colitis induced by readministration of TNBS. 111 This induction of IL-10 was essential for the expansion of a population of regulatory T cells that was identifi ed as a critical mediator of the amelioration of colitis and possessed characteristics of "natural" Tregs. Note that a role for IL-10 in the expansion of natural Tregs has, to our knowledge, not been previously described, although there are indications that it might be necessary for their functional activation, in particular their ability to release TGF-β. 112 Given the increased frequency and intact in vitro function of Foxp3+ Tregs in colonic lymphoid tissue of IBD patients, the question arises as to whether the induction of such "natural" Tregs is likely to benefi t such patients. There are, however, indications that the expansion of Tregs may have protective effects in patients with IBS or pouchitis. 95, 96 Cell wall components of the probiotic mixture VSL#3 can stimulate the maturation of murine BMDCs 36 and strongly induce IL-10 production from human blood and colonic lamina propria DCs. 27 In addition, they are capable of decreasing basal IL-12 secretion in human blood DCs and of downregulating the LPS-induced increase in the percentage of IL-12-producing blood DCs, while leaving the percentage of IL-10+ DCs unchanged. 27 When naïve allogeneic CD4+ T cells were activated in the presence of DCs stimulated with VSL#3 cell wall components, the proportion of IFN-γ-producing cells was signifi cantly reduced compared to either LPS-treated or unstimulated DCs, while the proportion of IL-4-or IL-10-producing cells was not significantly altered. 27 These results indicate that cell wall components of VSL#3 do not prime DCs for the generation of Th1 T-cell responses, but they do not predict the IL-10-dependent induction of regulatory T cells as seen in TNBS-induced colitis. 111 It is possible, however, that cell wall components are not responsible for the observed effects.
VSL#3 also signifi cantly inhibited the development of DSS-induced colitis and had remarkable therapeutic effects in established colitis. 113 These effects were shown to be due to probiotic DNA, which when given orally could inhibit disease activity and improve histologic scores to a similar extent as whole live bacteria. In addition, a single subcutaneous (s.c.) administration of probiotic DNA protected against TNBS-induced colitis and spontaneous colitis in IL-10 −/− mice. Of note, intragastric or s.c. administration of E. coli (DH5a) DNA also provided signifi cant protection from DSS-induced colitis. This confi rms that immunostimulatory DNA (ISS-DNA) sequences are a common property of certain bacterial and viral genomes. ISS-DNA sequences and their synthetic oligodeoxynucleotide (ODN) analogs contain unmethylated CpG dinucleotides within consensus sequences, termed CpG motifs, and can exert a variety of effects on macrophages, NK cells, B cells, and DCs. Studies with other ISS-ODNs in the DSS-induced model of colitis suggest that protection is mainly mediated by the production of immunoregulatory type 1 IFN (IFN-α/β) by plasmacytoid DCs. 114 In this model, type 1 IFN acts mainly, but not exclusively, by suppressing the infl ammatory response of activated macrophages. Since IFN-α has also been implicated in the regulation of Tcell responses, it will be of interest to determine whether such regulatory mechanisms are operative in VSL#3-associated amelioration of T cell-mediated models of colitis. In addition, organ culture experiments of colonic biopsy specimens from patients with active UC suggest that reduced production of proinfl ammatory cytokines is another potential mechanism by which VSL#3 DNA can protect against intestinal infl ammation. 66 
Probiotics in allergic diseases
Recent decades have witnessed a marked increase in the incidence of atopic diseases in industrialized countries. According to the "hygiene hypothesis," a relative lack of microbial stimuli in infancy and early childhood due to increased hygiene results in an imbalance between Th1-and Th2-type immune responses that favors the development of IgE-mediated allergies. However, over the same period of time, there has also been an increase in the incidence of diseases that are characterized by a predominantly Th1-polarized T-cell response. This suggests that immunoregulatory mechanisms capable of controlling both Th1 and Th2 responses do not fully mature in the relative absence of microbial stimuli. While much research has focused on early exposure to infectious agents, it is becoming increasingly recognized that commensal bacteria, which provide the fi rst and major source of microbial exposure, play a central role not only in Th1/Th2 polarization but also in inducing the appropriate regulatory mechanisms. It is also under investigation what role (if any) probiotics have on T regulatory cells. 115, 116 There are indications that the composition of commensal bacteria differs between children who develop atopic diseases and those who do not, and between children from countries with a high or low incidence of atopic disease. 117 However, to date, the differences identifi ed are not consistent between studies. In addition, a recent large multinational prospective study failed to detect an association between the time of colonization with any particular culturable bacterial group and the development of atopic eczema or sensitization to food allergens during the fi rst 18 months of life. 118 Primary allergy prevention trials with probiotics The hope of altering intestinal microbial balance and thereby modulating the polarization of helper T-cell responses have prompted numerous studies examining the potential role of probiotic strains in the primary prevention or treatment of atopic diseases. To date, the results of fi ve randomized placebo-controlled clinical trials of probiotics in the primary prevention of allergic disease have been published (see Table 5 ). All of these trials enrolled infants at high risk of developing allergy, usually defi ned as ≥1 family member having an allergic disease. In all studies except one, 119 the mothers received the supplement for the last weeks of pregnancy. After that, the study design becomes more variable, with the supplement being given to the lactating mother for varying periods, or to the infant directly until 6 months postnatally. Only one study supplemented until 12 months postnatally. 120 Assessment of allergic manifestations occurred at various time points during the fi rst and/or second year of life. In 2001, Kalliomäki et al. reported that LGG supplementation of pregnant women and later their infants resulted in a 50% reduction in the risk of eczema by the age of 2 years. This protective effect was maintained at the ages of 4 and 7 years. 122, 123 However, others were unable to confi rm a preventative effect of LGG supplementation, 124, 125 and the results of primary prevention trials using other probiotics are variable and not as impressive as those obtained by Kalliomäki et al. 121 (as summarized in Table 5 ). In the trials that examined the risk of other manifestations of allergic disease, probiotic supplementation did not show signifi cant effects on allergic rhinitis, food hypersensitivity, or asthma. [119] [120] [121] 124 In three of the trials, the rates of sensitization also did not differ signifi cantly between the probiotic and the placebo group. 121, 124, 125 Supplementation with L. reuteri ATCC 55730 lowered the incidence of skin prick reactivity in infants with mothers with allergies. 120 In contrast, ingestion of L. acidophilus LAVRI for the fi rst 6 months of life raised the rate of sensitization to a variety of food and inhalant allergens tested. 119 In addition, this and the recent LGG trial showed a signifi cantly greater frequency of wheezing or wheezing bronchitis in the probiotic compared with the placebo groups. 119, 125 Wheezing in infancy may be a risk factor for developing asthma later. Of note, Kalliomäki et al. 123 reported that the risk of both allergic rhinitis and asthma showed a tendency to be increased in the probiotic (LGG) compared with the placebo group at the 7-year follow-up. This makes it advisable to exert great caution in the use of probiotics in the prevention of allergic disease. Several other primary prevention trials are underway, 126 and it will be of great interest whether any of them reveal similarly concerning fi ndings.
121
In the original primary prevention trial with LGG, 121 analysis of data from a subset of women who breast-fed their infants for at least 3 months suggested that LGG supplementation of mothers during late pregnancy and lactation reduced the incidence of atopic eczema in their infants by increasing immunosuppressive TGF-β2 levels in breast milk. 127 In another study, however, low, rather than high, TGF-β2 levels in colostrum and milk tended to be associated with reduced sensitization and decreased incidence of IgE-associated eczema. 128 The induction of low-grade infl ammation has been proposed as a mechanism of the prevention of eczema by supplementation with LGG, L. rhamnosus LC705, B. breve Bb99, and Propionibacterium freudenreichii ssp. shermanii in combination with a prebiotic. 124, 129 This was based on an analysis of plasma levels of cytokines and infl ammatory markers in a randomly selected subgroup of participants in a large primary prevention trial, which indicated that increased plasma C-reactive pro tein (CRP) concentrations in infants at 6 months of age were associated with decreased risk of eczema and allergic disease at 2 years of age after adjustment for probiotic use. 129 This was also observed in a separate analysis of the placebo group. Plasma IL-10 concentrations were higher in the probiotic group and, paradoxically, correlated positively with CRP. Induction of low-grade infl ammation has also been proposed as a mechanism for therapeutic effects of probiotic supplementation in atopic dermatitis. 130 Interestingly, in that trial the very same combination of probiotics was used, but without added prebiotic, and was not found to have an infl ammatory effect but to also increase serum IL-10 levels. In contrast, treatment with LGG alone was associated with increased serum CRP and IL-6 concentrations in the subgroup of children with IgE-associated atopic eczema/ dermatitis syndrome.
Clinical trials of probiotics in the treatment of allergic diseases Studies in adults have largely not revealed any significant effect of probiotic supplementation in allergic rhinitis or asthma, 126 with the exception of several Japanese trials that suggest improved symptom/medication scores in patients with allergic rhinitis. However, the above studies are diffi cult to critically evaluate because of a lack of detailed information on the methods and procedures. Several clinical trials addressed the effectiveness of probiotic supplementation compared with placebo in the treatment of eczema or atopic dermatitis in infants or children. Ingestion of LGG for periods ranging from 4 to 12 weeks has been associated with signifi cant decreases or greater changes in Scoring Atopic Dermatitis (SCORAD) scores compared with placebo in some small studies, but not in several more recent and larger trials. Others were unable to detect signifi cant differences in the group overall, but found the LGGassociated improvements to be signifi cant in subgroups of children with IgE-associated disease. 131 In the same study, a combination of four probiotics (LGG, L. rhamnosus LC705, B. breve Bb99, and Propionibacterium freudenreichii ssp. shermanii) did not have a signifi cant effect. 131 Interestingly, the same four probiotics given in combination with a prebiotic reduced the incidence of eczema and atopic eczema and tended to reduce IgEassociated diseases overall in a primary prevention trial. 124 This may suggest that probiotics have different effects in developing compared with in established disease. Alternatively, the addition of prebiotic galactooligosaccharides may have been the decisive difference, although clear evidence of its bifi dogenic effect is still lacking. The combination of L. rhamnosus plus Bifidobacterium lactis (the strains were not specifi ed) also signifi cantly improved SCORAD scores only in the subset of food-sensitized children. 132 In young children (aged 6-18 months) with moderate or severe atopic dermatitis, supplementation with Lactobacillus fermen-tum VRI 003 PCC or placebo for 8 weeks was associated with a signifi cant reduction in the SCORAD index in the probiotic group, but not in the placebo group, although the difference between the groups after 16 weeks was not statistically signifi cant. 133 Cytokine production by PBMCs in response to polyclonal stimuli was not affected in participants of trials where probiotic supplementation did not show a significant effect. 134, 135 In contrast, improvements in SCORAD scores were associated with increased IFN-γ production in studies where probiotic supplementation was beneficial at least in certain subgroups of patients. 136, 137 In addition, the induction of low-grade infl ammation, as indicated by increased serum CRP and IL-6 levels, has been proposed as a mechanism. 130 Note, however, that in the above study, serum cytokine concentrations were below the detection limit in the majority of samples, including in almost 80% of the IL-6 samples. In the other studies, suffi cient blood samples were available only from subsets of study participants and no information was provided on how representative these children were of the whole study population. 136, 137 In addition, in one of these investigations signifi cant differences in baseline IFN-γ production between the probiotic and placebo groups were not taken into account, raising the question of whether the observed effects were really attributable to probiotic supplementation, particularly given that allergen-specifi c IFN-γ responses were not signifi cantly altered. 137 Probiotics in animal models of sensitization and allergic manifestations Because of these methodological shortcomings, the available data from clinical trials provides little insight into the mechanisms accounting for the strain-specifi c benefi ts of probiotic supplementation. Animal studies are beginning to unravel some of the immunological changes that accompany ingestion of established and potential probiotics and that may be of benefi t in allergic diseases. Most of these studies have focused on the sensitization process, which generally is not affected by probiotic supplementation in primary prevention trials. The most frequently used animal model of sensitization takes advantage of the fact that Balb/c mice are genetically predisposed toward the elaboration of Th2-polarized T-cell responses. These mice are injected i.p. with antigen, most commonly ovalbumin (OVA), in conjunction with aluminum hydroxide or a similar adjuvant. The effects of oral supplementation with various probiotic strains are then assessed by measuring serum levels of antigen-specifi c and total IgE production and the elaboration of Th1 and Th2 cytokines in splenocytes restimulated with OVA ex vivo.
The available data indicate that numerous LAB strains are capable of inhibiting total and OVA-specifi c IgE production when administered orally before or concomitant with sensitization (see Table 6 ). Notably, many strains are effective even when heat-killed (see Table 7 ). The associated cytokine patterns in OVA-stimulated splenocytes from LAB-fed mice are highly strain dependent and indicate that different mechanisms are involved. As summarized in Tables 6 and 7 , reduced serum levels of OVA-specifi c IgE can be associated with enhanced production of Th1 cytokines, decreased synthesis of Th2 cytokines, or both. However, in several studies IFN-γ production has been reported to be unaffected or even reduced, and in some instances both Th1 and Th2 cytokines are downregulated. In contrast, oral administration of L. rhamnosus HN001 before and during OVA sensitization increased both Th1 (IL-12, IL-18, and IFN-γ) and Th2 (IL-4 and IL-5) cytokines in splenocytes restimulated with OVA ex vivo. 138 Unfortunately, OVA-specifi c or total IgE levels were not determined in this study.
Two studies examined the effect of oral probiotic administration in murine models of asthma, in which i.p. sensitization with OVA was followed by intranasal OVA challenge. 139, 140 Note that one of these studies used a design resembling that of human primary prevention trials in that the probiotic supplementation was started at birth and continued throughout sensitization and challenge. 140 In these studies, oral administration of L. reuteri ATCC 23272, 139 LGG, or Bifi dobacterium animalis ssp. lactis Bb-12 140 signifi cantly decreased airway hyperresponsiveness and the infl ux of eosinophils and macrophages in bronchoalveolar lavage fl uid obtained 24 h after intranasal challenge. This was not associated with a Th1 polarization of the cytokine response in either of the studies. Instead, upregulation of systemic, though not pulmonary, activity of IDO was observed after oral administration of L. reuteri ATCC 23272. 139 IDO is an important immune control enzyme and mediator of peripheral tolerance, and its stimulation suggests the induction of regulatory mechanisms. Such a mechanism was shown more directly to be involved in the dampening of airway hyperreactivity after oral administration of LGG or B. animalis ssp. lactis Bb-12. 140 Both probiotics signifi cantly increased the number of natural Tregs (Foxp3+ CD4+ T cells) in the lungs of asthmatic mice, with Bb-12 showing greater effectiveness. Note that both Bb-12 and LGG induce only weak or partial maturation and little IL-12 production in human MDDCs. 30, 141 Whereas Bb-12 strongly stimulates MDDC synthesis of IL-10, LGG only moderately enhances it. Similar results have been reported from in vitro stimulation of human PBMCs with these LAB strains. 33, [142] [143] [144] These in vitro results are in keeping with the ability of these probiotic strains to induce regulatory mechanisms, rather than Th1 cytokine polarization, in vivo. Cytokine production in response to OVA restimulation was assessed in mesenteric lymph nodes
In one of the few studies to investigate the therapeutic rather than preventative effects of oral LAB supplementation, L. plantarum ATCC 8014 was identifi ed as a strain that strongly induces IL-10 and far less IL-12 in human MDDCs, although the resulting DCs primed naïve allogeneic CD4+ T cells for the production of high levels of IFN-γ along with IL-10. 145 When L. plantarum was used as an adjuvant in sublingual immunotherapy in established murine asthma, airway hyperresponsiveness was signifi cantly reduced compared with phosphate-buffered saline, whereas OVA alone or L. plantarum alone only induced nonsignifi cant reductions. This was not due to effects on OVA-specifi c IgE titers, the percentage of OVA-specifi c IL-5-producing splenocytes, or the activity of natural Tregs. Instead, L. plantarum markedly increased the proportion of OVA-specifi c proliferating T cells in cervical/maxillary lymph nodes. What role, if any, this enhanced proliferation plays in its benefi cial effect in this therapeutic asthma model remains to be established.
Few other studies addressed the therapeutic rather than preventative effects of oral LAB administration. In a model of established allergic rhinitis, in which i.p. OVA sensitization and s.c. boosting were followed by intranasal OVA challenge, 3 days of supplementation with L. acidophilus L92 and L. fermentum CP34 were suffi cient to signifi cantly reduce allergen-specifi c IgE. 146 Milk fermented with these or several other Lactobacillus strains was also effective. In a similar experimental model of allergic rhinitis, but with a longer duration of sensitization and also of probiotic administration, L. acidophilus L-55 reduced OVA-specifi c IgE as measured by passive cutaneous anaphylaxis. 147 It also lessened sneezing and nasal rubbing, the effect becoming signifi cant 2 weeks after the beginning of probiotic treatment and lasting throughout the treatment period. In a murine model of food allergy where mice were orally sensitized by intragastric administration of OVA together with cholera toxin, therapeutic administration of B. bifi dum BGN4 inhibited OVA-specifi c IgE production, while increasing IFN-γ and decreasing IL-6 secretion by OVA-stimulated splenocytes and diminishing the number of degranulated mast cells in ear and tongue tissue. 148 These effects were somewhat smaller than those seen after preventative treatment with the same strain, but this may have been due to the much shorter treatment period, which was 2 weeks compared with 7 weeks in the prevention study.
Probiotics in liver diseases and cancer
Although beyond the aims of the present manuscript, a brief mention of the potential impact of probiotics on chronic liver diseases and cancer is in order.
The effectiveness of lactulose as the only available treatment for encephalopathy in liver cirrhosis has provided a rationale for the use of probiotics in chronic liver diseases. Indeed, this is mostly based on two major mechanisms, that is, the ability to augment the intestinal barrier function and to prevent the translocation of bacteria. 149 Both mechanisms represent the rationale for the use of probiotics to prevent major complications of liver cirrhosis such as the development of a hyperdynamic circulatory state or spontaneous bacterial peritonitis, with the former being the background for the establishment of portal hypertension. 150 While solid data 
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from human studies are awaited to confi rm animal evidence, 151 the use of probiotics is considered safe in patients with chronic liver diseases, with the possible exception of end-stage functionally impaired liver cirrhosis. Based on the immunomodulatory impact of probiotics, the possibility that these may manifest signifi cant effects on the rapidly growing clinical problem of nonalcoholic fatty liver disease should not be ruled out. 152 It is well established that the etiopathogenesis of cancer involves several immune-mediated pathways, 153 particularly in the mucosal epithelia. 17, 154 A signifi cant effi cacy of probiotics on cancer development is suggested by several lines of scientifi c evidence and hypotheses, including the increase in immune cell activation and the suppression of bacteria converting procarcinogens. 155 Most data were obtained from cases of colon and breast carcinomas. In the former, prevention was fi rst achieved in animal models and was ascribed to the signifi cant anti-infl ammatory effect of probiotics. 156 Of note, this is in agreement with data obtained in clinical entities characterized by chronic infl ammation and higher carcinoma prevalence such as UC, as previously illustrated. In the case of breast cancer, on the other hand, suggested benefi cial effects of probiotics appear to be mediated by an increase of the antitumor surveillance immune activity. 157 In both cases, however, more solid data are encouraged and awaited in prospective randomized studies of suffi cient comparison power. Careful evaluation is also recommended in specifi c intensive care cases, as strongly suggested by data in patients with severe acute pancreatitis. 158 167 or a combination of those two strains with L. paracasei Lpc-37. 168 Interestingly, a similar mixture, but consisting of different strains (B. animalis ssp. lactis Bb-12 and Lactobacillus paracasei ssp. paracasei CRL-431) did not enhance phagocytosis at any of the four doses tested. 169 The effect size is frequently small and of questionable clinical relevance, although subjects with low innate immune responses may benefi t signifi cantly. 160, 161, 166 Of note, even though several small studies indicated that L. casei Shirota supplementation could increase NK cell and phagocytic activity, one of the probiotic supplementation studies with the highest methodological quality did not. 170 In this randomized placebocontrolled trial, all volunteers were kept on a controlled diet throughout the 2-week stabilization, 4-week treatment, and 2-week follow-up, periods. 170 None of the immune parameters under investigation was significantly affected by supplementation with L. casei strain Shirota. Besides NK cell activity, phagocytic, and respiratory burst activity, these included lymphocyte subset distribution, serum levels of IgM, IgG, IgA, and IgE, PBMC production of IL-1β, IL-2, and IFN-γ in response to LPS stimulation, and delayed-type hypersensitivity responses to eight recall antigens.
Probiotic supplementation in healthy volunteers
A few other studies have addressed the ex vivo cytokine production of PBMCs from volunteers who had consumed probiotics, and they generally found few, if any, effects. 169, 171 In contrast, supplementation of volunteers with L. fermentum ECET5716 for 2 weeks before and 2 weeks after vaccination with an inactivated trivalent infl uenza vaccine increased serum IL-12 levels before vaccination, and enhanced vaccine-induced elevations in serum TNF-α. 172 It also induced signifi cantly higher levels of specifi c IgA, but not IgG or IgM, compared with the placebo group. Minor adjuvant effects have also been reported for LGG or L. paracasei ssp. paracasei CRL431, 173 a combination of probiotics (LGG, L. rhamnosus LC705, B. breve Bbi99, and P. freudenreichii ssp. shermanii) plus galactooligosaccharides, 174 and L. paracasei ssp. paracasei F19. 175 Overall, these results suggest that several probiotic strains may have the ability to enhance nonspecifi c immune responses, but the effects on adaptive cellular and humoral immune responses seem to be for the most part minor.
Identifi cation of active probiotics components and receptor usage
The sometimes identical, sometimes differential effects of viable and nonviable bacteria suggest that metabolic or secreted factors as well as structural or other cellular components mediate certain immunomodulatory activities of probiotics 47, 139, 176 (Tables 3, 4 , 6, and 7). But the viability requirement depends not only on the immunomodulatory function under investigation but also on the bacterial strain. 44, 177 This suggests, and other data confi rm, 178 that even members of the same species differ substantially in their composition or their production of secreted mediators. Various experiments indicate that the ability to induce the secretion of various cytokines is mediated to a large extent by cell wall components. 177, 179, 180 In particular, peptidoglycans have been implicated in IL-12 induction in splenocytes, 178 while lipoteichoic acids are involved in the stimulation of TNF-α production in macrophages and splenocytes. 181 In addition, DNA has been shown to mediate a variety of immunomodulatory effects of certain probiotic strains both in vitro and in vivo. 48, 113, 177 Note that ISS-DNA sequences have been identifi ed in a variety of probiotic strains, including LGG, 182 Lactobacillus delbrueckii ssp. bulgaricus NIAI B6, 183 Lactobacillus gasseri OLL2716, 184 and B. longum BB536. 185 The ISS-ODN from B. longum BB536 and LGG exhibited immunomodulatory activity in OVA-immunized mice after oral and i.p. administration, respectively. 186, 187 Recognition of bacteria is mediated by a variety of pattern recognition receptors, the most important of which are TLRs and nucleotide-binding oligomerization domain (NOD) proteins. TLR usage by LAB strains is species-as well as activity-specifi c (see Table 8 ), probably partly attributable to the considerable variation in the cell wall composition even of members of the same species. 178 The TLRs identifi ed as mediating certain activities of probiotics include TLR2, TLR9, and NOD2
188 (see Table 8 ). Their ligands are peptidoglycans and lipoteichoic acid from Gram-positive bacteria in the case of TLR2, and CpG DNA in the case of TLR9, while NOD2 recognizes muramyl dipeptide, a constituent of peptidoglycans from both Gram-positive and Gramnegative bacteria. This further supports an important role for cell wall components and DNA in the immunomodulatory activities of probiotics. TLR4 recognizes LPS of Gram-negative bacteria, and its implication in macrophage TNF-α production in response to L. plantarum 189 is therefore unexpected. Note that some in vitro and in vivo effects of probiotics were found not to require TLR2, TLR4, or TLR9. 107, 180, 190 However, defi ciency of MyD88, an adapter molecule for TLR signaling, abolished the investigated activities. It remains to be established whether other TLRs or a MyD88-dependent, but TLR-independent, pathway is involved.
Final comments and thoughts
While there is substantial evidence from in vitro and animal studies that known and potential probiotics have strain-specifi c immunomodulatory capacities, the results from human intervention trials are far less convincing. This may be partly a question of the dose, which is often similar in animal studies and human trials despite the enormous difference in weight and intestinal size. Dose-response studies are urgently required, especially since there are indications that certain in vitro effects are seen only at low bacterial doses 39 and that high doses may produce opposite effects to those obtained at low doses. 47 The results of a human supplementation trial also suggest that lower doses can be more effective than higher doses. 166 It might be advisable to determine whether a probiotic has any effect and whether it retains this effect when used in combination with another probiotic before proceeding with a dose-response study that ultimately shows that a probiotic combination has no effect at four different doses. 169 Another potential explanation for the differential effectiveness of probiotics in animals and humans might be that the composition of the intestinal microfl ora is likely to vary to a much greater extent between individual humans than between individual mice that are kept in the same environment and fed the same diet. Since in vitro studies suggest considerable interactions between different commensal and probiotic strains, 30, 31 human responses to probiotic treatment might differ depending on the composition of the individual's endogenous fl ora. Genetic differences in the expression of pattern recognition receptors and other factors contributing to the response to bacterial signals are also likely to contribute to the variable responses to probiotic treatment.
Despite the mostly minor immunomodulatory effects of probiotics in human supplementation studies, there are some concerning fi ndings, such as the increased rate of sensitization or greater frequency of wheezing in participants of primary intervention trials who received L. acidophilus LAVRI-A1 or LGG, 119, 143 or the more severe endoscopic recurrence seen in CD patients treated with LGG. 89 Note also that there is some concern that strongly Th1-promoting strains may aggravate Th1-mediated autoimmune diseases. There are several studies showing the exacerbation of experimental autoimmune encephalomyelitis (EAE), a Th1-mediated model of multiple sclerosis, with certain Lactobacillus strains, including the well-established probiotic L. casei Shirota. [191] [192] [193] However, other probiotic strains are capable of ameliorating EAE, 194 and other experimental autoimmune diseases that are known to be Th1 mediated, such as various models of rheumatoid arthritis [195] [196] [197] or type 1 diabetes. 198 Together, these fi ndings highlight the need for care in choosing appropriate probiotic strains for particular applications. In this process, it needs to be taken into account that the response to probiotic supplementation depends on the immunological status of the host, as demonstrated by in vitro 98, 199 and in vivo experiments. 168, 200 What ultimately counts in the search for functional foods to modulate the immune response is that well-tolerated and effective nutrients are needed, and probiotics are currently among the best candidates to play this critical role in future epidemics of metabolic and infl ammatory conditions.
